Bioinformatic Exploration of Hub Genes and Potential Therapeutic Drugs for Endothelial Dysfunction in Hypoxic Pulmonary Hypertension

Table 2

Researching results in CMAP.

	CMAP name	Cell line	Score	Function	Targets
Hypoxia 3 h vs. Ctrl	Levonorgestrel	VCAP	0.9699	Ovulation, cervical mucus changes, and hormone therapy	Progesterone receptor, 3-oxo-5-alpha-steroid 4-dehydrogenase 1, and 4-estrogen receptor alpha
	Procaterol	NEU	-0.8991	Bronchodilator	Beta-2 adrenergic receptor
Hypoxia 24 h vs. Ctrl	Naltrindole	SKBR3	0.9009	Antagonist analog of opiate enkephalin	Delta opioid receptor
	Avanafil	HT29	-0.9231	Inhibition of cGMP-specific phosphodiesterase type 5 (PDE5)	cGMP-specific 3,5-cyclic phosphodiesterase
Hypoxia 48 h vs. Ctrl	Fluoxetine	HA1E	0.9193	Selective serotonin reuptake inhibitor (SSRI)	Sodium-dependent serotonin transporter
	Lestaurtinib	HCC515	-0.8995	Inhibition of FMS-like tyrosine kinase 3 (FLT3) autophosphorylation	FMS-like tyrosine kinase 3 (FLT3)